• $8.1 million Q2 revenue, up 77% on Q1 and 310% on Q2 FY2024
• $12.6 million revenue H1 FY 2025, up 267% on previous half
• Positive operating cash flow of $1.5 million for the Quarter

Bioxyne Limited (ASX:BXN) has reported a record second quarter of trading, continuing the outstanding result of its previous Q1. This was driven by several major contracts, a growing customer base, and an expanding product range. The standout performer was the company's Breathe Life Science (BLS) Australia subsidiary, which was granted a Good Manufacturing Practice (GMP) licence to manufacture medical cannabis products, as well as Australia's first licence to manufacture Psilocybin and MDMA. The company achieved $8.1 million in Q2 revenue, up 77% on Q1 and 310% on the same period last year. H1 FY 2025 revenue reached $12.6 million, a 267% increase on the previous half. Bioxyne reported positive operating cash flow of $1.5 million for the quarter, from cash receipts of $7.4 million. The company invested $1.3 million in H1 FY2025 to increase its manufacturing capacity, which will drive further revenue growth in the second half. Bioxyne expects to shortly receive regulatory approval to export its Dr Watson Pharmaceutical products to the UK, and is also completing a business case for a proposed GMP manufacturing facility in Europe.

The company is projecting revenue growth in individual product categories in the next two quarters of between 30% to 50%.

Bioxyne is focused on growing its manufacturing customer base, increasing market share for its Dr Watson branded pharmaceutical products in Australia, growing the Dr Watson branded health and wellness products in Europe, and introducing its proprietary PCC probiotic product into its existing global distribution channels.